Children with growth hormone deficiency are currently treated with daily injections of recombinant growth hormone. The burden of 365 injections per year and cold chain storage causes a poor medication adherence. Long-acting growth hormones were developed to decrease injection frequency and therefore to promote a better therapeutic compliance. This paper discusses what long-acting drugs are currently on the market and their mechanism of action, and identifies the patient groups that may benefit from them.
